Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China

Virus Research

Volumn 155, Issue 1, 2011, Pages 137-146

  Wang, Suting ^a   Nie, Jianhui ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Genetic; HIV 1; Neutralization; Pseudovirus; Subtype

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; GENE CLUSTER; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE BC; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ANTIBODIES, NEUTRALIZING; CHINA; CLUSTER ANALYSIS; CROSS PROTECTION; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650538583     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.09.012     Document Type: Article

References (49)

1. Back N.K., Smit L., De Jong J.J., Keulen W., Schutten M., Goudsmit J., Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994, 199(2):431-438.
2. Barbato G., Bianchi E., Ingallinella P., Hurni W.H., Miller M.D., Ciliberto G., Cortese R., Bazzo R., Shiver J.W., Pessi A. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 2003, 330(5):1101-1115.
3. Bhattacharya T., Daniels M., Heckerman D., Foley B., Frahm N., Kadie C., Carlson J., Yusim K., McMahon B., Gaschen B., Mallal S., Mullins J.I., Nickle D.C., Herbeck J., Rousseau C., Learn G.H., Miura T., Brander C., Walker B., Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007, 315(5818):1583-1586.
4. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78(23):13232-13252.
5. Brown B.K., Wieczorek L., Sanders-Buell E., Rosa B.A., Robb M.L., Birx D.L., Michael N.L., McCutchan F.E., Polonis V.R. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008, 375(2):529-538.
6. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300(5628):2065-2071.
7. Chong H., Hong K., Zhang C., Nie J., Song A., Kong W., Wang Y. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J. Acquir. Immune Defic. Syndr. 2008, 47(5):535-543.
8. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303(5666):2019-2022.
9. Dubay J.W., Roberts S.J., Hahn B.H., Hunter E. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J. Virol. 1992, 66(11):6616-6625.
10. Edwards T.G., Wyss S., Reeves J.D., Zolla-Pazner S., Hoxie J.A., Doms R.W., Baribaud F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 2002, 76(6):2683-2691.
11. Ellerbrok H., D'Auriol L., Vaquero C., Sitbon M. Functional tolerance of the human immunodeficiency virus type 1 envelope signal peptide to mutations in the amino-terminal and hydrophobic regions. J. Virol. 1992, 66(8):5114-5118.
12. Freed E.O., Martin M.A. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 1996, 70(1):341-351.
13. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296(5577):2354-2360.
14. Geretti A.M. HIV-1 subtypes: epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 2006, 19(1):1-7.
15. Gray E.S., Meyers T., Gray G., Montefiori D.C., Morris L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS. Med. 2006, 3(7):e255.
16. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20(16):W13-W23.
17. Ivey-Hoyle M., Clark R.K., Rosenberg M. The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site. J. Virol. 1991, 65(5):2682-2685.
18. Kulkarni S.S., Lapedes A., Tang H., Gnanakaran S., Daniels M.G., Zhang M., Bhattacharya T., Li M., Polonis V.R., McCutchan F.E., Morris L., Ellenberger D., Butera S.T., Bollinger R.C., Korber B.T., Paranjape R.S., Montefiori D.C. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 2009, 385(2):505-520.
19. Kurle S., Tripathy S., Jadhav S., Agnihotri K., Paranjape R. Full-length gag sequences of HIV type 1 subtype C recent seroconverters from Pune, India. AIDS Res. Hum. Retroviruses 2004, 20(10):1113-1118.
20. Li Y., Bergeron J.J., Luo L., Ou W.J., Thomas D.Y., Kang C.Y. Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(18):9606-9611.
21. Li Y., Luo L., Thomas D.Y., Kang C.Y. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding. Virology 2000, 272(2):417-428.
22. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
23. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., Derdeyn C.A. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 2006, 80(11):5211-5218.
24. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 2006, 80(23):11776-11790.
25. Liu S.Y., Xing H., Zhang Y.Z., Ruan Y.H., Quan Y., Zhu J.H., Shao Y.M. Dynamic variation of HIV-1 CRF07_BC env gene in early HIV-1 infection. Zhonghua Shi Yan. He. Lin. Chuang. Bing. Du Xue. Za Zhi. 2008, 22(4):290-292.
26. Lu L., Jia M., Ma Y., Yang L., Chen Z., Ho D.D., Jiang Y., Zhang L. The changing face of HIV in China. Nature 2008, 455(7213):609-611.
27. Lynch R.M., Shen T., Gnanakaran S., Derdeyn C.A. Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res. Hum. Retroviruses 2009, 25(3):237-248.
28. Ma L., Guo Y., Yuan L., Huang Y., Sun J., Qu S., Yu X., Meng Z., He X., Jiang S., Shao Y. Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang province of China. Retrovirology 2009, 6:45.
29. Milich L., Margolin B.H., Swanstrom R. Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology 1997, 239(1):108-118.
30. Moore J.P., Burton D.R. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat. Med. 2004, 10(8):769-771.
31. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 1996, 70(3):1863-1872.
32. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67(11):6642-6647.
33. Njai H.F., Gali Y., Vanham G., Clybergh C., Jennes W., Vidal N., Butel C., Mpoudi-Ngolle E., Peeters M., Arien K.K. The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006, 3:40.
34. Patel M.B., Hoffman N.G., Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 2008, 82(2):903-916.
35. Piyasirisilp S., McCutchan F.E., Carr J.K., Sanders-Buell E., Liu W., Chen J., Wagner R., Wolf H., Shao Y., Lai S., Beyrer C., Yu X.F. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J. Virol. 2000, 74(23):11286-11295.
36. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1994, 10(12):1651-1658.
37. Rademeyer C., Moore P.L., Taylor N., Martin D.P., Choge I.A., Gray E.S., Sheppard H.W., Gray C., Morris L., Williamson C. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007, 368(1):172-181.
38. Speck R.F., Wehrly K., Platt E.J., Atchison R.E., Charo I.F., Kabat D., Chesebro B., Goldsmith M.A. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J. Virol. 1997, 71(9):7136-7139.
39. Stamatos N.M., Mascola J.R., Kalyanaraman V.S., Louder M.K., Frampton L.M., Birx D.L., VanCott T.C. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J. Virol. 1998, 72(12):9656-9667.
40. Steimer K.S., Scandella C.J., Skiles P.V., Haigwood N.L. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 1991, 254(5028):105-108.
41. van der Kuyl A.C., Cornelissen M. Identifying HIV-1 dual infections. Retrovirology 2007, 4:67.
42. Wang Y., Song A., Xu S., Li X., Chong H., Zhao C., Nie J., Zhang C. Impact of HIV-1 genetic diversity in China on the measurement of viral load. J. Med. Virol. 2008, 80(1):1-8.
43. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
44. Yuan X., Yu X., Lee T.H., Essex M. Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J. Virol. 1993, 67(11):6387-6394.
45. Zhang L., Chen Z., Cao Y., Yu J., Li G., Yu W., Yin N., Mei S., Li L., Balfe P., He T., Ba L., Zhang F., Lin H.H., Yuen M.F., Lai C.L., Ho D.D. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J. Virol. 2004, 78(24):13591-13599.
46. Zhang Y., Lu L., Ba L., Liu L., Yang L., Jia M., Wang H., Fang Q., Shi Y., Yan W., Chang G., Zhang L., Ho D.D., Chen Z. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS. Med. 2006, 3(11):e443.
47. Zhang H., Rola M., West J.T., Tully D.C., Kubis P., He J., Kankasa C., Wood C. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 2010, 400(2):164-174.
48. Zhu T., Mo H., Wang N., Nam D.S., Cao Y., Koup R.A., Ho D.D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261(5125):1179-1181.
49. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75(22):10892-10905.